Heart-on-a-chip systems: disease modeling and drug screening applications

Area of Science:

• Biomedical Engineering
• Cardiovascular Research
• Drug Development

Background:

• Cardiovascular disease (CVD) is a leading global cause of death and economic burden.
• Traditional animal models for CVD research often fail to accurately replicate human physiology, leading to poor therapeutic translation.
• There is a critical need for human-relevant models to study CVD, assess cardiotoxicity, and evaluate drug efficacy.

Purpose of the Study:

• To review the components and applications of Heart-on-a-chip (HoC) systems.
• To highlight the use of HoC systems in modeling cardiovascular disease, assessing drug toxicity, and evaluating efficacy.
• To discuss future perspectives and challenges in the field of HoC technology.

Main Methods:

• Review of contemporary reports on Heart-on-a-chip systems.
• Analysis of microfluidics, tissue engineering, and other technologies used in HoC development.
• Discussion of multi-organ-on-a-chip platforms incorporating HoC systems.

Main Results:

• Heart-on-a-chip systems leverage microfluidics and tissue engineering to create human-relevant models.
• These systems enable real-time measurements and characterization of cardiac tissue behavior.
• HoC platforms show promise in disease modeling, cardiotoxicity assessment, and drug efficacy evaluation.

Conclusions:

• Heart-on-a-chip technology offers a significant advancement over traditional animal models for cardiovascular research.
• Standardization is crucial for accelerating the widespread adoption and impact of HoC platforms.
• HoC systems have the potential to revolutionize drug development and improve patient outcomes for cardiovascular diseases.